Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

[1]  W. Xue,et al.  Rare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication , 2022, EBioMedicine.

[2]  Melissa Hum,et al.  Germline Variants Associated with Nasopharyngeal Carcinoma Predisposition Identified through Whole-Exome Sequencing , 2022, Cancers.

[3]  R. Sun,et al.  Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. , 2022, JAMA oncology.

[4]  B. Cirauqui,et al.  SEOM-TTCC clinical guideline in nasopharynx cancer (2021) , 2022, Clinical and Translational Oncology.

[5]  Tingting Hu,et al.  Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials , 2021, European Archives of Oto-Rhino-Laryngology.

[6]  W. Xue,et al.  A comprehensive analysis of genetic diversity of EBV reveals potential high-risk subtypes associated with nasopharyngeal carcinoma in China , 2021, Virus evolution.

[7]  J. Machiels,et al.  Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Y. Mao,et al.  Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. , 2020, Oral oncology.

[9]  A. King,et al.  Integrating post-radiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Li Lin,et al.  Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma , 2020, Cancer.

[11]  Trevor J Pugh,et al.  Translational Genomics of Nasopharyngeal Cancer. , 2020, Seminars in cancer biology.

[12]  Li-Zhi Liu,et al.  Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma , 2019, Cancer communications.

[13]  Bin Zhang,et al.  Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma , 2019, JAMA network open.

[14]  X. Li,et al.  Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  C. Qian,et al.  Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. , 2019, European journal of cancer.

[16]  Chien-Jen Chen,et al.  Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma , 2019, Scientific Reports.

[17]  Xihong Lin,et al.  Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma , 2019, Nature Genetics.

[18]  Brian O'Sullivan,et al.  The addition of pretreatment plasma Epstein–Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification , 2019, International journal of cancer.

[19]  J. Xia,et al.  Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort , 2018, Journal of Cancer.

[20]  R. Fåhraeus,et al.  EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers , 2018, Cancers.

[21]  J. Chan,et al.  Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China , 2018, Cancer.

[22]  J. Bourhis,et al.  A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Ying Sun,et al.  Prognostic value of plasma Epstein–Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy , 2017, Chinese journal of cancer.

[24]  B. O'Sullivan,et al.  A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10‐year outcomes for efficacy and toxicity , 2017, Cancer.

[25]  Kwok Wai Lo,et al.  Epstein–Barr virus infection and nasopharyngeal carcinoma , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[26]  M. Kano,et al.  The influence of human papillomavirus on nasopharyngeal carcinoma in Japan. , 2017, Auris, nasus, larynx.

[27]  Ying Sun,et al.  Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. , 2017, European journal of cancer.

[28]  R. Sun,et al.  Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. , 2017, European journal of cancer.

[29]  B. Wenig,et al.  Update From The 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Nasopharynx , 2017, Head and Neck Pathology.

[30]  Simion I. Chiosea,et al.  Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations , 2017, Nature Communications.

[31]  P. Khong,et al.  Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma , 2016, Oncotarget.

[32]  H. Adami,et al.  Sibship size, birth order and risk of nasopharyngeal carcinoma and infectious mononucleosis: a nationwide study in Sweden. , 2016, International journal of epidemiology.

[33]  P. Sham,et al.  Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma , 2016, Proceedings of the National Academy of Sciences.

[34]  Sung-Bae Kim,et al.  Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). , 2016, Radiotherapy and Oncology.

[35]  S. Leung,et al.  Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma , 2015, Cancer.

[36]  Rensheng Wang,et al.  Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  Y. Shih,et al.  Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. , 2014, International journal of radiation oncology, biology, physics.

[38]  F. Feng,et al.  Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. , 2014, International journal of radiation oncology, biology, physics.

[39]  H. Sze,et al.  Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  Lifang Yang,et al.  Therapeutic Evaluation of Epstein-Barr Virus-encoded Latent Membrane Protein-1 Targeted DNAzyme for Treating of Nasopharyngeal Carcinomas , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Xia He,et al.  Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results. , 2013, Future oncology.

[42]  Ling-Ling Zhang,et al.  A randomized clinical trial comparing prophylactic upper versus whole‐neck irradiation in the treatment of patients with node‐negative nasopharyngeal carcinoma , 2013, Cancer.

[43]  M. Robinson,et al.  Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population , 2013, Infectious Agents and Cancer.

[44]  W. Liang,et al.  Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  Ying Sun,et al.  Progress report of a randomized trial comparing long‐term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China , 2013, Cancer.

[46]  Chaosu Hu,et al.  Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma , 2013, Journal of Cancer Research and Clinical Oncology.

[47]  A. King,et al.  A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  E. Tan,et al.  A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  T. Ciuleanu,et al.  Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Chong Zhao,et al.  Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. , 2012, International journal of radiation oncology, biology, physics.

[51]  X. Ke,et al.  EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model , 2011, Medical oncology.

[52]  B. O'Sullivan,et al.  A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[53]  Qing Liu,et al.  The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials , 2010, BMC Cancer.

[54]  E. Sturgis,et al.  Human papillomavirus and WHO type I nasopharyngeal carcinoma , 2010, The Laryngoscope.

[55]  B. O'Sullivan,et al.  Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. , 2010, Journal of the National Cancer Institute.

[56]  I. Chitapanarux,et al.  Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. , 2007, European journal of cancer.

[57]  T. Mok,et al.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. , 2005, Journal of the National Cancer Institute.

[58]  A. Taylor,et al.  Intensity-modulated radiotherapy—what is it? , 2004, Cancer imaging : the official publication of the International Cancer Imaging Society.